NEW YORK (January 29, 2020)—TB Alliance and partners announced the launch of the ERA4TB (European Regimen Accelerator for Tuberculosis) project
NEW YORK (January 27, 2020)—New peer-reviewed research has evaluated the efficacy of different doses and schedules of linezolid for the treatment
NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine.
The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines.
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to
The public health progress in the World Health Organization’s Global Tuberculosis (TB) Report 2019 this year can be found in
TB Alliance applauds the Stop TB Partnership’s TB REACH program for investing in efforts to combat tuberculosis (TB). The $15.4
NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S.
On July 28th in South Africa, more than 100 members of the TB research community marched under the Louder than
